A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia

AstraZeneca20 enrolled

Overview

The purpose of the study is to establish the efficacy, safety and tolerability of rosuvastatin in children and adolescents with homozygous familial hypercholesterolemia.

This is a randomized, double-blind, placebo-controlled, multi-center, cross-over study of the efficacy, safety and tolerability rosuvastatin in children and adolescents (aged 6 to \<18 years) with homozygous familial hypercholesterolemia (HoFH). The study is designed to assess the efficacy of rosuvastatin 20 mg compared to placebo on lipids, lipoproteins and apolipoproteins in pediatric patients with HoFH. The outcome measures to be assessed include low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglycerides, non-HDL-C, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, apolipoprotein B (ApoB), apolipoprotein A 1 (ApoA-1) and ApoB/ApoA-1 following 6 weeks of treatment with rosuvastatin 20 mg or placebo. Pharmacokinetic data of the trough plasma exposure of rosuvastatin will also be assessed in these pediatric patients with HoFH.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Homozygous Familial Hypercholesterolemia (HoFH)

Interventions

Rosuvastatin 20mgDRUG

Active drug will be taken taken orally, QD, either in the morning or in the evening

PlaceboDRUG

Will be taken taken orally, QD, either in the morning or in the evening

Eligibility

Sex: ALLMin age: 6 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Prior to any study related procedures being performed, provision of written informed consent from a parent/both parents or guardian and statement of assent from the child or adolescent (if required by Institutional Review Board \[IRB\] or Independent Ethics Committee \[EC\] according to local regulations and guidelines). Communication between the Investigator, patient/guardian and child/adolescent to confirm understanding and required compliance with the requirements of the study. 2. Male and female children and adolescents (aged 6 to \<18 years) with at least 1 of the following criteria: Documentation of genetic testing confirming 2 mutated alleles of the LDL receptor gene locus; and/or Documented untreated LDL C \>500 mg/dL (12.9 mmol/L) and triglyceride (TG) \<300 mg/dL (3.4 mmol/L) and at least 1 of the following criteria: 1. Tendinous and/or cutaneous xanthoma prior to 10 years of age; or 2. Documentation of HoFH in both parents by: * genetic and/or * clinical criteria 3. Negative pregnancy test (b human chorionic gonadotropin analysis) prior to baseline in females of child bearing potential: * Female patients of child bearing potential must adhere to a pregnancy prevention method (abstinence, chemical, or mechanical) during the study and 3 months following the last dose. * Male patients should refrain from fathering a child (including sperm donation) during the study and up to 3 months following the last dose; and 4. Willing to follow all study procedures including adherence to dietary guidelines, study visits, fasting blood draws, and compliance with study treatment regimens. Exclusion Criteria 1. History of statin inducted myopathy or serious hypersensitivity reaction to other HMG CoA reductase inhibitors (statins), including rosuvastatin, at Visit 1. 2. Fasting serum glucose of \>9.99 mmol/L (180 mg/dL) or glycosylated hemoglobin \>9% at Visit 1 or patients with a history of diabetic ketoacidosis within the past year. 3. Uncontrolled hypothyroidism defined as thyroid stimulating hormone (TSH) \>1.5 times the upper limit of normal (ULN) at Visit 1 or patients whose thyroid replacement therapy was initiated or modified within the last 3 months prior to Visit 2. 4. Current active liver disease or hepatic dysfunction (except a confirmed diagnosis of Gilbert's disease) as defined as elevations of 1.5 times the upper limit of normal (ULN) for any age in any of the following liver function tests at Visit 1: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), or bilirubin. 5. Definite or suspected personal history or family history of clinically significant adverse drug reactions (ADRs), or hypersensitivity to drugs with a similar chemical structure to rosuvastatin as well as other statins.

Locations (9)

Research Site

Brussels (Woluwé-St-Lambert), Belgium

Research Site

Chicoutimi, Quebec, Canada

Research Site

København Ø, Denmark

Research Site

Haifa, Israel

Outcomes

Primary Outcomes

LDL-Cholesterol (mg/dL)

Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment

Time frame: Samples taken on Day 42 (week 6) and on day 84 (week 12)

LDL-Cholesterol (mmol/L)

Change in low density lipoprotein cholesterol (LDL C) following 6 weeks of rosuvastatin 20 mg compared to 6 weeks of placebo treatment

Time frame: Samples taken on Day 42 (week 6) and on day 84 (week 12)

Secondary Outcomes

TC (mg/dL)

Efficacy in terms of total cholesterol (TC)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

TC (mmol/L)

Efficacy in terms of total cholesterol (TC)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

Non-HDL C (mg/dL)

Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

Non-HDL C (mmol/L)

Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

ApoB (mg/dL)

Efficacy in terms of apolipoprotein B (ApoB)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

ApoB (g/L)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Kuala Lumpur, Malaysia

Research Site

Kubang Kerian, Malaysia

Research Site

Amsterdam, Netherlands

Research Site

Goteborg, Netherlands

Research Site

Taipei, Taiwan

Efficacy in terms of apolipoprotein B (ApoB)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

HDL-C (mg/dL)

Efficacy in terms of high density lipoprotein cholesterol (HDL C)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

HDL-C (mmol/L)

Efficacy in terms of high density lipoprotein cholesterol (HDL C)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

LDL-C, Not on Apheresis (mg/dL)

Efficacy in terms of low density lipoprotein cholesterol (LDL C) following 6 weeks rosuvastatin 20 mg or placebo treatment in patients not treated with Apheresis

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

LDL-C, Not on Apheresis (mmol/L)

Efficacy in terms of low density lipoprotein cholesterol (LDL C) following 6 weeks rosuvastatin 20 mg or placebo treatment in patients not treated with Apheresis

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

LDL-C From End of Placebo (mg/dL)

Change in low density lipoprotein cholesterol (LDL C) from end of placebo period to 6, 12, and 18 weeks of therapy with rosuvastatin 20 mg

Time frame: Samples taken at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18) and Day 168 (week 24)

LDL-C From End of Placebo (mmol/L)

Change in low density lipoprotein cholesterol (LDL C) from end of placebo period to 6, 12, and 18 weeks of therapy with rosuvastatin 20 mg

Time frame: Samples taken at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18) and Day 168 (week 24)

Trough Concentrations

Pharmacokinetic profile in terms of trough concentrations. Cross-over phase results based on measurements taken after 6 weeks active treatment (rosuvastatin) in the cross-over phase. Maintenance phase results based on measurements taken after 6 weeks active treatment (rosuvastatin) in the maintenance phase.

Time frame: Samples taken 24 hours post-dose at Day 42 (week 6), Day 84 (week 12), Day 126 (week 18)

Adverse Events

Safety and tolerability will be described in terms of frequency and severity of adverse events

Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)

AE's Leading to Discontinuation

Safety and tolerability will be described in terms of rate of discontinuations due to adverse events

Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)

Abnormal Serum Levels

Safety and tolerability will be described in terms of abnormal serum laboratory values. The reported parameters are not the only ones measured, but rather those for which abnormailities were found

Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)

Height

Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.

Time frame: Week 0 (start of cross-over), weeks 6, week 12 and week 18

Height Z-score

Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.

Time frame: Week 0 (start of cross-over), weeks 6, week 12 and week 18

Weight

Safety and tolerability will be described in terms of growth, including height (linear growth \[cm and standard deviation (SD) score\]), and weight.

Time frame: Week 0 (start of cross-over), weeks 6, week 12 and week 18

Tanner Stage

Stages for fem (Pubic hair, Breasts): 1. (Preadol,Preadol) 2. (Sparse, lightly pigmented, medial border of labia,Breast and papilla elevated as small mound; areolar diam incr) 3. (Darker, beginning to curl, incr amount, Breast and areola enlarged, no contour separation) 4. (Course, curly, abundant but less amount in adult,Areola and papilla form secondary mound) 5. (Adult fem triangle, spread to medial surface of thighs,Mature, nipple projects, areola part of general breast contour) For males (Pubic hair, Penis, Testes) 1=(None,Preadol,Preadol) 2=(Scanty, long, light pigm,Slight enl,Enl scrotum, pink texture alt) 3=(Darker, starts to curl, small amount,Longer,Larger) 4=(Resembles adult type, but less in quant; course, curly,Larger; glans and breadth increased in size,Larger, scrotum dark) 5=(Adult distr, spread to medial thighs,Adult size,Adult size). Progr at a normal rate is preferred. Regr is not preferred.

Time frame: Week 0 (start of cross-over)

TG (mg/dL)

Efficacy in terms of triglycerides (TG)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

TG (mmol/L)

Efficacy in terms of triglycerides (TG)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

LDL C/HDL C

Efficacy in terms of low density lipoprotein cholesterol (LDL C) / high density lipoprotein cholesterol (HDL C)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

TC/HDL C

Efficacy in terms of total cholesterol (TC) / high density lipoprotein cholesterol (HDL C)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

Non-HDL C/HDL C

Efficacy in terms of non-high density lipoprotein cholesterol (non-HDL C) / HDL C

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

ApoB/ApoA

Efficacy in terms of apolipoprotein B (ApoB) / apolipoprotein A (ApoA)

Time frame: Samples taken at Day 42 (week 6) and Day 84 (week 12)

Urinalysis Abnormalitites

Safety and tolerability will be described in terms of abnormal urine laboratory values

Time frame: Week 0, week 6, week 12 and week 18

ECG Abnormalities

Safety and tolerability will be described in terms of abnormal electro cardio gram (ECG)

Time frame: Week 0

Physical Exam Abnormalitites

Safety and tolerability will be described in terms of abnormal physical examinations. Only parameters for which abnormalities were found are reported.

Time frame: Screening, Week 0, week 6, week 12 and week 18, week 24

Abnormal Vital Signs

Safety and tolerability will be described in terms of abnormal vital signs

Time frame: From screening (5-6weeks before dose) up to the last visit Day 168 (approximately 30 weeks after screening)